Systemic treatment of soft-tissue sarcoma - Gold standard and novel therapies

Nature Reviews Clinical Oncology

Volumn 11, Issue 4, 2014, Pages 187-202

  Linch, Mark ^a   Miah, Aisha B ^a   Thway, Khin ^a   Judson, Ian R ^a   Benson, Charlotte ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CABAZITAXEL; CABOZANTINIB; CEDIRANIB; CYCLOPHOSPHAMIDE; DACARBAZINE; DOCETAXEL; DOXORUBICIN; ERIBULIN; EVEROLIMUS; EVOFOSFAMIDE; GEMCITABINE; IFOSFAMIDE; IMATINIB; LETROZOLE; NAVELBINE; PALIFOSFAMIDE; PAZOPANIB; PLACEBO; PREDNISOLONE; RAPAMYCIN; REGORAFENIB; RIDAFOROLIMUS; SUNITINIB; TEMSIROLIMUS; TIVANTINIB; TRABECTEDIN; UNINDEXED DRUG; CANCER VACCINE; HISTONE DEACETYLASE INHIBITOR; MDM2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; PRODRUG; PROTEIN KINASE INHIBITOR; PROTEIN MDM2;

ADOPTIVE IMMUNOTHERAPY; ALVEOLAR SOFT PART SARCOMA; ANGIOSARCOMA; BONE MARROW SUPPRESSION; BRAIN DISEASE; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CHEMOSENSITIVITY; CLEAR CELL SARCOMA; DEDIFFERENTIATED LIPOSARCOMA; DERMATOFIBROSARCOMA PROTUBERANS; DOSE RESPONSE; DRUG MEGADOSE; DRUG POTENCY; DRUG RESPONSE; DRUG TOLERABILITY; ENDOMETRIAL STROMAL TUMOR; ENDOMETRIUM SARCOMA; EPITHELIOID SARCOMA; GASTROINTESTINAL STROMAL TUMOR; GENE AMPLIFICATION; GENE EXPRESSION; GENE TRANSLOCATION; GENETIC ASSOCIATION; GENOMICS; HEMANGIOENDOTHELIOMA; HISTOLOGY; HUMAN; IMMUNOLOGICAL SYNAPSE; LEIOMYOSARCOMA; LIPOSARCOMA; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; MYXOSARCOMA; NONHUMAN; OVERALL SURVIVAL; PATHOGENESIS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; RHINOPHARYNGITIS; SALPINGOOOPHORECTOMY; SEPSIS; SOFT TISSUE SARCOMA; SOLITARY FIBROUS TUMOR; STOMATITIS; SYNOVIAL SARCOMA; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; UTERUS SARCOMA; WELL DIFFERENTIATED LIPOSARCOMA; ALGORITHM; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; GENETICS; IMMUNOTHERAPY; MOLECULARLY TARGETED THERAPY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; SARCOMA;

ALGORITHMS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANCER VACCINES; COMBINED MODALITY THERAPY; DRUG RESISTANCE, NEOPLASM; HISTONE DEACETYLASE INHIBITORS; HUMANS; IMMUNOTHERAPY; IMMUNOTHERAPY, ADOPTIVE; MOLECULAR TARGETED THERAPY; PRODRUGS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MDM2; SARCOMA;

EID: 84908122111     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2014.26     Document Type: Review

References (190)

1. Clark, M. A., Fisher, C., Judson, I. & Thomas, J. M. Soft-tissue sarcomas in adults. N. Engl. J. Med. 353, 701-711 (2005).
2. Fletcher, C. D. M., Unni, K. K., Mertens, F. (Eds) WHO classification of tumours of soft tissue and bone (IARC Press, Lyon, 2013).
3. National Cancer Intelligence Newtork. Bone and soft tissue sarcomas UK incidence and survival: 1996 to 2010 [online], http://www.ncin.org.uk/view?rid=2353 (2013).
4. Jemal, A., Center, M. M., Ward, E. & Thun, M. J. Cancer occurrence. Methods Mol. Biol. 471, 3-29 (2009).
5. Rossi, C. R. et al. Adherence to treatment guidelines for primary sarcomas affects patient survival: a side study of the European CONnective TIssue CAncer NETwork (CONTICANET). Ann. Oncol. 24, 1685-1691 (2013).
6. Santoro, A. et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J. Clin. Oncol. 13, 1537-1545 (1995).
7. Judson, I. et al. Results of a randomised phase III trial (EORTC 62012) of single agent doxorubicin versus doxorubicin plus ifosfamide as fi rst line chemotherapy for patients with advanced or metastatic soft tissue sarcoma: a survival study by the EORTC soft tissue and bone sarcoma group [abstract]. Ann. Oncol. 23 (Suppl. 9), ixe28 LBA7 (2012).
8. Aurias, A., Rimbaut, C., Buffe, D., Zucker, J. M. & Mazabraud, A. Translocation involving chromosome 22 in Ewing's sarcoma. A cytogenetic study of four fresh tumors. Cancer Genet. Cytogenet. 12, 21-25 (1984).
9. de Alava, E. et al. EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma. J. Clin. Oncol. 16, 1248-1255 (1998).
10. Fisher, C. The diversity of soft tissue tumours with EWSR1 gene rearrangements: a review. Histopathology 64, 134-150 (2014).
11. Thway, K. & Fisher, C. Tumors with EWSR1-CREB1 and EWSR1-ATF1 fusions: the current status. Am. J. Surg. Pathol. 36, e1-e11 (2012).
12. Coindre, J. M. Molecular biology of soft-tissue sarcomas [French]. Bull. Cancer 97, 1337-1345 (2010).
13. Pervaiz, N. et al. A systematic meta-Analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer 113, 573-581 (2008).
14. Le Cesne, A., Van Glabbeke, M. & Woll, P. J. The end of adjuvant chemotherapy era with doxorubicin-based regimen in resected high-grade soft tissue sarcoma: Pooled analysis of the two STBSG-EORTC phase III clinical trials [a bstract]. J. Clin. Oncol. 26 (Suppl.), a10525 (2008).
15. Woll P. J.,et al. Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre r andomised controlled trial Lancet Oncol. 13, 1045-1054, 2012).
16. Look Hong, N. J. et al. Neoadjuvant chemoradiotherapy for patients with high-risk extremity and truncal sarcomas: a 10-year single institution retrospective study. Eur. J. Cancer 49, 875-883 (2013).
17. Greto, D. et al. Neoadjuvant treatment of soft tissue sarcoma. Radiol. Med. http://dx.doi.org/10.1007/s11547-013-0331-6.
18. Sleijfer, S. et al. Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on lar ge series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG). Eur. J. Cancer 46, 72-83 (2010).
19. Bramwell, V. H., Anderson, D. & Charette, M. L. Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft-tissue sarcoma: a meta-Analysis and clinical practice guideline. Sarcoma 4, 103-112 (2000) .
20. Volkova, M. & Russell, R. 3rd. Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment. Curr. Cardiol. Rev. 7, 214-220 (2011).
21. Tascilar, M., Loos, W. J., Seynaeve, C., Verweij, J. & Sleijfer, S. The pharmacologic basis of ifosfamide use in adult patients with advanced soft tissue sarcomas. Oncologist 12, 1351-1360 (2007).
22. Patel, S. R. et al. High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies-dose-response and schedule dependence. J. Clin. Oncol. 15, 2378-2384 (1997).
23. Bui-Nguyen, B. et al. High-dose chemotherapy consolidation for chemosensitive advanced soft tissue sarcoma patients: an open-label, randomized controlled trial. Ann. Oncol. 23, 777-784 (2012).
24. Jones, B., Komarnitsky, P., Miller, G. T., Amedio, J. & Wallner, B. P. Anticancer activity of stabilized palifosfamide in vivo: schedule effects, oral bioavailability, and enhanced activity with docetaxel and doxorubicin. Anticancer Drugs 23, 173-184 (2012).
25. Verschraegen, C. F. et al. A phase II, randomized, controlled trial of palifosfamide plus doxorubicin versus doxorubicin in patients with soft tissue sarcoma (PICASSO) [abstract]. J. Clin. Oncol. 28 (Suppl.), a10004 (2010).
26. Hoffmann, C. et al. What is the price of cure for the treatment of pelvic Ewing sarcoma [abstract 3820] presented at the ECCO17-ESMO38-ESTRO32 meeting (Amsterdam, 2013).
27. Demetri, G. D. et al. Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemother apy. J. Clin. Oncol. 31, 2485-2492 (2013).
28. Mansi, J. L. et al. A phase I-II study of ifosfamide in combination with adriamycin in the treatment of adult soft tissue sarcoma. Eur. J. Cancer Clin. Oncol. 24, 1439-1443 (1988).
29. Gan joo, K. N. et al. A randomised phase III multicenter open label study comparing TH3-2 in combination with doxorubicin versus doxorubicin alone in subjects with locally advanced unresectable or metastatic soft tissue sarcoma [abstract]. Prese nted at the CTOS meeting (Prague, 2012).
30. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT01440088 (2014).
31. Sharma, S., Takyar, S., Manson , S. C., Powell, S. & Penel, N. Efficacy and safety of pharmacological interventions in second-or later-line treatment of patients with advanced soft tissue sarcoma: a systematic review. BMC Cancer 13, 385 (2013).
32. Maki, R. G. et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. J. Clin. Oncol. 25, 2755-2763 (2007).
33. Hensley, M. L. et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J. Clin. Oncol. 20, 2824-2831 (2002).
34. Pautier, P. et al. Randomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM study). Oncologist 17, 1213-1220 (2012).
35. UK Clinical Research Network Study Portfolio. Public.ukcrn.org.uk [online], http://public.ukcrn.org.uk/search/StudyDetail.aspx?StudyID=8444 (2014).
36. Dileo P.,et al. Gemcitabine and vinorelbine combination chemotherapy for patients with advanced soft tissue sarcomas: results of a phase II trial Cancer 109, 1863-1869, 2007).
37. Garcia-Del-Muro, X. et al. Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study. J. Cl in. Oncol. 29, 2528-2533 (2011).
38. Le Cesne, A. et al. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J. Clin. Oncol. 23, 576-584 (2005).
39. Pommier, Y. et al. DNA sequence-And structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent an titumor compound from the Caribbean tunicate Ecteinascidia turbinata. Biochemistry 35, 13303-13309 (1996).
40. Di Giandomenico, S. et al. Mode of action of trabectedin in myxoid liposarcomas. Oncogene http://dx.doi.org/10.1038/onc.2013.462 (2013).
41. Germano, G. et al. Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell 23, 249-262 (2013).
42. Sleijfer, S. et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-sof t tissue and bone sarcoma group (EORTC study 62043). J. Clin. Oncol. 27, 3126-3132 (2009).
43. van der Graaf, W. T. et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 379, 1879-1886 (2012).
44. Mir, O. et al. Feasibility of metronomic oral cyclophosphamide plus prednisolone in elderly patients with inoperable or metastatic soft tissue sarcoma. Eur. J. Cancer 47, 515-519 (2011).
45. Judson, I. et al. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advan ced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur. J. Cancer 37, 870-877 (2001).
46. Grosso, F. et al. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol. 8, 595-602 (2007).
47. Forni, C. et al. Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors. Mol. Cancer Ther. 8, 449-457 (2009).
48. Demetri, G. D. et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide : results of a randomized phase II study of two different schedules. J. Clin. Oncol. 27, 4188-4196 (2009).
49. Le Cesne, A. et al. A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas. Eur. J. Cancer 48, 3036-3044 (2012).
50. Hendifar, A. E. et al. Results of the randomized phase III trial of trabectedin (T) versus doxorubicin-based chemotherapy (DXCT) as first-line therapy in patients (pts) with translocation-related sarcoma (TRS) [abstract]. J. Clin. Oncol. 31 (Suppl.), a10517 (2013).
51. Spurrell, E. L., Fisher, C., Thomas, J. M. & Judson, I. R. Prognost ic factors in advanced synovial sarcoma: an analysis of 104 patients treated at the Royal Marsden Hospital. Ann. Oncol. 16, 437-444 (2005).
52. Rosen, G. et al. Synovial sarcoma. Uniform response of metastases to high dose ifosfamide. Cancer 73, 2506-2511 (1994).
53. Orbach, D. et al. Paediatric and adolescent alveolar soft part sarcoma: a joint series from European cooperative groups. Pediatr. Blood Cancer 60, 1826-1832 (2013).
54. Portera, C. A. Jr. et al. Alveolar soft part sarcoma: clinical course and patterns of metastasis in 70 patients treated at a single institution. Cancer 91, 585-591 (2001).
55. Kummar, S. et al. Cediranib for metastatic alveolar soft part sarcoma. J. Clin. Oncol. 31, 2296-2302 (2013).
56. Stacchiotti, S. et al. Sunitinib in advanced alveolar soft part sarcoma: evidence of a direct antitumor effect. Ann. Oncol. 22, 1682-1690 (2011).
57. US National Library of Medicine. Cl inicalTrials.gov [online], http://clinicaltrials.gov/show/NCT01337401 (2014).
58. US National Library of Medicine. ClinicalTrials gov [online] http://clinicaltrials.gov/show/NCT01391962 2014).
59. Davis, I. J. et al. Oncogenic MITF dysregulation in clear cell sarcoma: defining the MiT family of human cancers. Cancer Cell 9, 473-484 (2006).
60. Wagner, A. J. et al. Tivantinib (ARQ 197 ), a selective inhibitor of MET, in patients with microphthalmia transcription factor-Associated tumors: results of a multicenter phase 2 trial. Cancer 118, 5894-5902 (2012).
61. Kurzrock, R. et al. Activity of XL184 (cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J. Clin. Oncol. 29, 2660-2666 (2011).
62. Shimizu, A. et al. The dermatofibrosarcoma p rotuberans-Associated collagen type Ialpha1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB. Cancer Res. 59, 3719-3723 (1999).
63. Rutkowski, P. et al. Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J. Clin. Oncol. 28, 1772-1779 (2010).
64. US National Library of Medic ine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT01059656 (2014).
65. Hendrickson, M. R. et al. in Pathology and Genetics of Tumours of the Breast and Female Genital Organs (eds Tavassoli, F. A. & Devilee, P.) (IARC Press, Lyon, 2003).
66. Cheng, X. et al. Recurrence patterns and prognosis of endometrial stromal sarcoma and the potential of tyrosine kinase-inhibiting therapy. Gynecol. Oncol. 121, 323-327 (2011).
67. Malouf, G. G. et al. Impact of adjuvant treatment modalities on the management of patients with stages I-II endometrial stromal sarcoma. Ann. Oncol. 21, 2102-2106 (2010).
68. Pink, D. et al. Harm or benefit of hormonal treatment in metastatic low-grade endometrial stromal sarcoma: single center experience with 10 cases and review of the literature. Gynecol. Oncol. 101, 464-469 (2006).
69. Dahhan, T., Fons, G., Buist, M. R., Ten Kate, F. J. & van der Velden, J. The efficacy of hormonal treatment for residual or recurrent low-grade endometrial stromal sarco ma. A retrospective study. Eur. J. Obstet. Gynecol. Reprod. Biol. 144, 80-84 (2009).
70. ISRCTN. Current Controlled Trials [online], http://www.controlled-trials.com/ISRCTN43261139/PARaGoN (2014).
71. Chiang, S. & Oliva, E. Recent developments in uterine mesenchymal neoplasms. Histopathology 62, 124-137 (2013).
72. Schick, U. et al. Outcome and prognostic factors in endometrial stromal tumors: a Rare Cancer Network study. Int. J. Radiat. Oncol. Biol. Phys. 82, e757-e763 (2012).
73. Tanner, E. J., Garg, K., Leitao, M. M. Jr., Soslow, R. A. & Hensley, M. L. High grade undifferentiated uterine sarcoma: surgery, treatment, and survival outcomes. Gynecol. Oncol. 127, 27-31 (2012).
74. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT01979393 (2014).
75. Cassier, P. A. et al. A prospective epidemiological study of new incident GISTs during two consecutive years in Rhone Alpes region: incidence and molecular distribution of GIST in a E uropean region. Br. J. Cancer 103, 165-170 (2010).
76. Blanke, C. D. et al. Long-term results from a randomized phase II trial of standard-versus higher-dose imatinib mesylate for patients with un resectable or metastatic gastrointestinal stromal tumors expressing KIT. J. Clin. Oncol. 26, 620-625 (2008).
77. Linch, M., Claus, J. & Benson, C. Update on imatinib for gastrointestinal stromal tumors: duration of treatment. Onco Targets Ther. 6, 1011-1023 (2013).
78. Corless, C. L., Barnett, C. M. & Heinrich, M. C. Gastrointestinal stromal tumours: origin and molecular oncology. Nat. Rev. Cancer 11, 865-878 (2011).
79. Wagner A. J.,et al Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of m TORC1 in tumors. J. Clin. Oncol. 28, 835-840, 2010).
80. Kenerson, H., Folpe, A. L., Takayama, T. K. & Yeung, R. S. Activation of the mTOR pathway in sporadic angiomyolipomas and other peri vascular epithelioid cell neoplasms. Hum. Pathol. 38, 1361-1371 (2007).
81. Kozlowski, P. et al. Identification of 54 large deletions/duplications in TSC1 and TSC2 using MLPA, and genotype-phenotype correlations. Hum. Genet. 121, 389-400 (2007).
82. Bissler, J. J. et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomis ed, double-blind, placebo-controlled trial. Lancet 381, 817-824 (2013).
83. Italiano, A. et al. Treatment with the mTOR inhibitor temsirolimus in patients with malignant PEComa. Ann. Oncol. 21, 1135-1137 (2010).
84. Nilbert, M., Rydholm, A., Mitelman, F., Meltzer, P. S. & Mandahl, N. Characterization of the 12q13-15 amplicon in soft tissue tumors. Cancer Genet. Cytogenet. 83, 32-36 (1995).
85. Shimada, S. et al. The value of MDM2 and CDK4 amplification levels using real-time polymerase chain reaction for the differential diagnosis of liposarcomas and their histologic mimickers. Hum. Pathol. 37, 1123-1129 (2006).
86. Thway, K., Flora, R., Shah, C., Olmos, D. & Fisher, C. Diagnostic utility of p16, CDK4, and MDM2 as an immunohistochemical panel in distinguishing well-differentiated and dedifferentiated liposarcom as from other adipocytic tumors. Am. J. Surg. Pathol. 36, 462-469 (2012).
87. Jones, R. L., Fisher, C., Al-Muderis, O. & Judson, I. R. Differential sensitivity of liposarcoma subtypes to chemotherapy. Eur. J. Cancer 41, 2853-2860 (2005).
88. Martin-Liberal, J. et al. Clinical activity and tolerability of a 14-day infusional ifosfamide schedule in soft-tissue sarcoma. Sarcoma http://dx.doi.org/10.1155/2013/868973 (2013).
89. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT01913652 (2014).
90. Bai, R. L. et al. Halichond rin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data. J. Biol. Chem. 266, 15882-15889 (1991).
91. Schoffski, P. et al. Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes. Lancet Oncol. 12, 1045-1052 (2011).
92. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT01327885 (2014).
93. Italiano, A. et al. Clinical outcome of leiomyosarcomas of vascular origin: comparison with leiomyosarcomas of other origin. Ann. Oncol. 21, 1915-1921 (2010).
94. Farid, M. et al. The influence of primary site on outcomes in leiomyosarcoma: a review of clinicopathologic differences between uterine and extrauterine disease. Am. J. Clin. Oncol. 36, 368-374 (2013).
95. Leitao, M. M. et al. Tissue microarray immunohistochemical expression of estrogen, progesterone, and androgen receptors in uterin e leiomyomata and leiomyosarcoma. Cancer 101, 1455-1462 (2004).
96. O'Cearbhaill, R. et al. Treatment of advanced uterine leiomyosarcoma with aromatase inhibitors. Gynecol. Oncol. 116, 424-429 (2010).
97. Casper, E. S. et al. Phase II trial of paclitaxel in patients with soft-tissue sarcoma. Cancer Invest. 16, 442-446 (1998).
98. Penel, N. et al. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J. Clin. Oncol. 26, 5269-5274 (2008).
99. Errani, C. et al. A novel WWTR1-CAMTA1 gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sites. Genes Chromosomes Cancer 50, 644-653 (2011)
100. Trombetta D.,et al Translocation t(7;19)(q22;q13)-A recurrent chromosome aberration in pseudomyogenic hemangioendothelioma Cancer Genet. 204, 211-215, 2011).
101. Belotti, D. et al. The microtubule-Affecting drug paclitaxel has antiangiogenic activity. Clin. Cancer Res. 2, 1843-1849 (1996).
102. Italiano, A. et al. Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas. Cancer 118, 3330-3336 (2012).
103. Antonescu, C. R. et al. KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors. Cancer Res. 69, 7175-7179 (2009).
104. Cranshaw, I. M. et al. Clinical outcomes of extra-thoracic solitary fibrous tumours. Eur. J. Surg. Oncol. 35, 994-998 (2009).
105. Constantinidou, A. et al. Conventional anthracycline-based chemotherapy has limited efficacy in solitary fibrous tumour. Acta Oncol. 51, 550-554 (2012).
106. Levard, A. et al. Outcome of patients with advanced solitary fibrous tumors: the Centre Leon Berard experience. BMC Cancer 13, 109 (2013).
107. Stacchiotti, S. et al. Response to chemotherapy of solitary fibrous tumour: a retrospective study. Eur. J. Cancer 49, 2376-2383 (2013).
108. Wignall, O. J., Moskovic, E. C., Thway, K. & Thomas, J. M. Solitary fibrous tumors of the soft tissues: review of the imaging and clinical features with histopathologic correlation. AJR Am. J. Roentgenol. 195, W55-W62 (2010).
109. Sawada, N. et al. Immunohistochemical localization of endothelial cell markers in solitary fibrous tumor. Pathol. Int. 52, 769-776 (2002).
110. Stac chiotti, S. et al. Sunitinib malate in solitary fibrous tumor (SFT). Ann. Oncol. 23, 3171-3179 (2012).
111. Pearce, L. R., Komander, D. & Alessi, D. R. The nuts and bolts of AGC protein kinases. Nat. Rev. Mol. Cell Biol. 11, 9-22 (2010).
112. Davis, M. I. et al. Comprehensive analysis of kinase inhibitor selectivity. Nat. Biotechnol. 29, 1046-1051 (2011).
113. Anastassiadis, T., Deacon, S. W., Devarajan, K., Ma, H. & Peterson, J. R. Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nat. Biotechnol. 29, 1039-1045 (2011).
114. Monks, A. et al. Sarcoma cell line sensitivity towards approved oncology drugs and investigational agents identifies distinct patterns of response which can be interr ogated with associated gene expression [abstract]. Mol. Cancer Ther. 12 (Suppl. 11), aC103 (2013).
115. Michels, S. et al. SRC signaling is crucial in the growth of synovial sarcoma cells. Cancer Res. 73, 2518-2528 (2013).
116. Trusolino, L., Bertotti, A. & Comoglio, P. M. MET signalling: principles and functions in development, organ regeneration and cancer. Nat. Rev. Mol. Cell Biol. 11, 834-848 (2010).
117. Ferracini, R. et al. The Met/HGF receptor is over-expressed in human osteosarcomas and is activated by either a paracrine or an autocrine circuit. Oncogene 10, 739-749 (1995).
118. Butrynski, J. E. et al. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N. Engl. J. Med. 363, 1727-1733 (2010).
119. Mossé , Y. P. et al. S afety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. Lancet Oncol. 14, 472-480 (2013).
120. US National Library of Medicine. ClinicalTrials.gov [online] http://clinicaltrials.gov/show/NCT01524926 (2014).
121. Fleuren, E. D. et al. Expression and clinical relevance of MET and ALK in Ewing sarcomas. Int. J. Cancer 133, 427-436 (2013).
122. Demicco E. G.,et al Involvement of the PI3K/Akt pathway in myxoid/round cell liposarcoma. Mod. Pathol. 25, 212-221, 2012).
123. Barretina, J. et al. Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat. Genet. 42, 715-721 (2010).
124. Kato, J., Matsushime, H., Hiebert, S. W., Ewen, M. E. & Sherr, C. J. Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4. Genes Dev. 7, 331-342 (1993).
125. Bloom, J. & Cross, F. R. Multiple levels of cyclin specificity in cell-cycle control. Nat. Rev. Mol. Cell Biol. 8, 149-160 (2007).
126. Dickson, M. A. et al. Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-Amplified well-differentiated or dedifferentiated liposarcoma. J. Clin. Oncol. 31, 2024-2028 (2013).
127. Luke, J. J. et al. The cyclin-dependent kinase inhibitor flavopiridol potentiates doxorubicin efficacy in advanced sarcomas: preclinical investigations and results of a phase I dose-escalation clinical trial. Clin. Cancer Res. 18, 2638-2647 (2012).
128. Okuno, S. et al. A phase 2 study of temsirolimus (CCI-779) in patients with soft tissue sarcomas: a study of the Mayo phase 2 consortium (P2C). Cancer 117, 3468-3475 (2011).
129. Quek, R. et al. Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors. Clin. Cancer Res. 17, 871-879 (2011).
130. Schwartz, G. K. et al. Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial. Lancet Oncol. 14, 371-382 (2013).
131. Endo, M. et al. Prognostic significance of AKT/mTOR and MAPK pathways and antitumor effect of mTOR inhibitor in NF1-related and sporadic malignant peripheral nerve sheath tumors. Clin. Cancer Res. 19, 450-461 (2013).
132. Cohen, E. E. et al. Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patients. Clin. Cancer Res. 18, 4785-4793 (2012).
133. Stacchiotti, S. et al. Sirolimus in advanced hemangioendothelioma [abstract]. J. Clin. Oncol. 31 (Suppl.), a10565 (2013).
134. Evans, D. G. et al. Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J. Med. Genet. 39, 311-314 (2002).
135. Downward, J. Targeting RAS and PI3K in lung cancer. Nat. Med. 14, 1315-1316 (2008).
136. Jessen, W. J. et al. MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors. J. Clin. Invest. 123, 340-347 (2013).
137. Su, L. et al. Deconstruction of the SS18-SSX fusion oncoprotein complex: insights into disease etiology and therapeutics. Cancer Cell 21, 333-347 (2012).
138. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT00878800 (2014).
139. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT01112384 (2014).
140. US N ational Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT00918489 (2014).
141. Kussie, P. H. et al. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 274, 948-953 (1996).
142. Manfredi, J. J. The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor. Genes Dev. 24, 1580-1589 (2010).
143. Ray-Coquard I.,et al. Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-Amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study Lancet Oncol. 13, 1133-1140, 2012).
144. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT01463696 (2014).
145. Brenner, J. C. et al. PARP-1 inhibition as a targeted strategy to treat Ewing's sarcoma. Cancer Res. 72, 1608-1613 (2012).
146. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT01583543 (2014).
147. Rosen, E. D. & Spiegelman, B. M. PPARgamma: a nuclear regulator of metabolism, differentiation, and cell growth. J. Biol. Chem. 276, 37731-37734 (2001).
148. Demetri, G. D. et al. Induction of solid tumor differentiation by the peroxisome proliferator-Activated receptor-gamma ligand troglitazone in patients with liposarcoma. Proc. Natl Acad. Sci. USA 96, 3951-3956 (1999 ).
149. Debrock, G. et al. A phase II trial with rosiglitazone in liposarcoma patients. Br. J. Cancer 89, 1409-1412 (2003).
150. Pishvaian, M. J. et al. A phase 1 study of efatutazone, an oral peroxisome proliferator-Activated receptor gamma agonist, administered to patients with advanced malignancies. Cancer 118, 5403-5413 (2012).
151. Maki, R. G. Future directions for immunotherapeutic intervention against sarcomas. Curr. Opin. Oncol. 18, 363-368 (2006).
152. Borden, E. C. et al. Phase II trials of interferons-Alpha and-beta in advanced sarcomas. J. Interferon Res. 12, 455-458 (1992).
153. Schuster, S. J. et al. Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J. Clin. Oncol. 29, 2787-2794 (2011).
154. Kantoff, P. W. et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363, 411-422 (2010).
155. Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723 (2010).
156. Wolchok, J. D. et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369, 122-133 (2013).
157. Ayyoub, M. et al. Identification of an SSX-2 epitope presented by dendritic cells to circulating autologous CD4+ T cells. J. Immunol. 172, 7206-7211 (2004).
158. Kawaguchi, S. et al. SYT-SSX breakpoint peptide vaccines in patients with synovial sarcoma: a study from the Japanese Musculoskeletal Oncology Group. Cancer Sci. 103, 1625-1630 (2012).
159. Pollack, S. M., Loggers, E. T., Rodler, E. T., Yee, C. & Jones, R. L. Immune-based therapies for sarcoma. Sarcoma 2011, 438940 (2011).
160. Hemminger, J. A. et al. The cancer-testis antigen NY-ESO-1 is highly expressed in myxoid and round cell subset of liposarcomas. Mod. Pathol. 26, 282-288 (2013).
161. Robbins, P. F. et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J. Clin. Oncol. 29, 917-924 (2011).
162. Maki, R. G. et al. A pilot study of anti-CTLA4 antibody ipilimumab in patients with synovial sarcoma. Sarcoma 2013, 168145 (2013).
163. US National Library of Medicine. Clin icalTrials.gov [online], http://clinicaltrials.gov/show/NCT01643278 (2014).
164. Ribas A.,Hodi F. S.,Callahan M.,Konto C.,Wolchok J Hepatotoxicity with combination of vemurafenib and ipilimumab. N. Engl. J. Med. 368 1365-1366, 2013).
165. Smith, T. J. Insulin-like growth factor-I regulation of immune function: a potential therapeutic target in autoimmune diseases? Pharmacol. Rev. 62, 199-236 (2010).
166. Cohen, B. D. et al. Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin. Cancer Res. 11, 2063-2073 (2005).
167. Olmos, D. et al. Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. Lancet Oncol. 11, 129-135 (2010).
168. Olmos, D. et al. Targeting the insulin-like growth factor 1 receptor in Ewing's sarcoma: reality and expectations. Sarcoma 2011, 402508 (2011).
169. Juergens, H. et al. Pre liminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma. J. Clin. Oncol. 29, 4534-4540 (2011).
170. Jassem, J. et al. Randomiz ed, open label, phase III trial of figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC) [abstract]. J. Clin. Oncol. 28 (Suppl. 15), a7500 (2010).
171. Sanfilippo, R. et al. Trabectedin in advanced uterine leiomyosarcomas: a retrospective case series analysis from two reference centers. Gynecol. Oncol. 123, 553-556 (2011).
172. M onk, B. J. et al. A phase II evaluation of trabectedin in the treatment of advanced, persistent, or recurrent uterine leiomyosarcoma: a gynecologic oncology group study. Gynecol. Oncol. 124, 48-52 (2012).
173. Talbot, S. M. et al. A phase II trial of temozolomide in patients with unresectable or metastatic soft tissue sarcoma. Cancer 98, 1942-1946 (2003).
174. Hensley, M. L. et al. Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study. Gynecol. Oncol. 115, 460-465 (2009).
175. Kassam, A. & Mandel, K. Metastatic hepatic epithelioid hemangioendothelioma in a teenage girl. J. Pediatr. Hematol. Oncol. 30, 550-552 (2008).
176. Salech, F. et al. Thalidomide for the treatment of metastatic hepatic epithelioid hemangioendothelioma: a case report with a long term follow-up. Ann. Hepatol. 10, 99-102 (2011).
177. Raphael, C., Hudson, E., Williams, L., Lester, J. F. & Savage, P. M. Successful treatment of metastatic hepatic epithelioid hemangioendothelioma with thalidomide: a case report. J. Med. Case Rep. 4, 413 (2010).
178. Mascarenhas, R. C. et al. Thalidomide inhibits the growth and progression of hepatic epithelioid hemangioendothelioma. Oncology 67, 471-475 (2004).
179. Sumrall, A., Fredericks, R., Berthold, A. & Shumaker, G. Lenalidomide stops progression of multifocal e pithelioid hemangioendothelioma including intracranial disease. J. Neurooncol. 97, 275-277 (2010).
180. Chevreau, C. et al. Sorafenib in patients with progressive epithelioid hemangioendothelioma: a phase 2 study by the French Sarcoma Group (GSF/GETO). Cancer 119, 2639-2644 (2013).
181. Gaur, S., Torabi, A. & O'Neill, T. J. Activity of angiogenesis inhibitors in metastatic epithelioid hemangioendothelioma: a case report. Cancer Biol. Med. 9, 133-136 (2012).
182. Trautmann, K., Bethke, A., Ehninger, G. & Folprecht, G. Bevacizumab for recurrent hemangioendothelioma. Acta Oncol. 50, 153-154 (2011).
183. Schlemmer, M. et a l. Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma group. Eur. J. Cancer 44, 2433-2436 (2008).
184. Nagano, T. et al. Docetaxel: a therapeutic option in the treatment of cutaneous angiosarcoma: report of 9 patients. Cancer 110, 648-651 (2007).
185. Skubitz, K. M. & Haddad, P. A. Paclitaxel and pegylated-liposomal doxorubicin are both active in angiosarcoma. Cancer 104, 361-366 (2005).
186. Stacchiotti S..et al Gemcitabine in advanced angiosarcoma: a retrospective case series analysis from the Italian Rare Cancer Network. Ann. Oncol. 23 501-508, 2012).
187. Maki, R. G. et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J. Clin. Oncol. 27, 3133-3140 (2009).
188. Chugh, R. et al. Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model. J. Clin. Oncol. 27, 3148-3153 (2009).
189. Agulnik, M. et al. An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. Ann. Oncol. 24, 257-263 (2013).
190. Yoo, C. e t al. Multicenter phase II study of everolimus in patients with metastatic or recurrent bone and soft-tissue sarcomas after failure of anthracycline and ifosfamide. Invest. New Drugs 31, 1602-1608 (2013).